Log in to save to my catalogue

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchy...

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchy...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7878213

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype

About this item

Full title

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype

Publisher

New York: Springer US

Journal title

Medical oncology (Northwood, London, England), 2021-03, Vol.38 (3), p.24-24, Article 24

Language

English

Formats

Publication information

Publisher

New York: Springer US

More information

Scope and Contents

Contents

A subset of colorectal cancer (CRC) with a mesenchymal phenotype (CMS4) displays an aggressive disease, with an increased risk of recurrence after surgery, reduced survival, and resistance to standard treatments. It has been shown that the AXL and TGFβ signaling pathways are involved in epithelial-to-mesenchymal transition, migration, metastatic sp...

Alternative Titles

Full title

Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7878213

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7878213

Other Identifiers

ISSN

1357-0560

E-ISSN

1559-131X

DOI

10.1007/s12032-021-01464-3

How to access this item